Kyowa Hakko Kirin, a Japan-based pharmaceutical and biotechnology company, has signed a clinical trial collaboration agreement with Bristol-Myers Squibb, a global biopharmaceutical company.
It was reported yesterday that the contract has been signed to conduct a Phase I/II combination trial with mogamulizumab, an anti-CCR4 antibody and Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor to treat advanced or metastatic solid tumours. Mogamulizumab is a new, humanised mAb directed against CC chemokine receptor type 4 (CCR4).
The trial will concentrate on assessing the safety, tolerability and anti-tumour activity of combining mogamulizumab and Opdivo as a potential treatment option for these patients.
(c) 2015 M2 COMMUNICATIONS, source M2 PressWIRE